Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRESTONE: Seribantumab in NRG1 Fusion Positive Solid Tumors
NCT04383210Phase 2Terminated
- Sponsor
- Elevation Oncology, Inc.
- Start
- Sep 2020
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of seribantumab in solid tumor, sponsored by Elevation Oncology, Inc.. Started Sep 2020; status: terminated.
02
Drugs
seribantumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04383210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383210.